Press Releases
Excerpt from the Press Release: SAN FRANCISCO, CA / ACCESSWIRE / September 29, 2022 / Napo Pharmaceuticals, Inc. (“Napo”), the wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today announced the activation by the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for Napo’s NP-300, a novel…
Read More
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat cancer, today announced the publication of a study in the New England Journal of Medicine entitled “GPRC5D-Targeted CAR T Cells for Myeloma.” The study was led by Dr. Eric Smith of the Dana-Farber Cancer…
Read More
Results showed evidence of clinical activity for cirtuvivint in advanced cancer patients Excerpt from the Press Release: SAN DIEGO, Sept. 29, 2022 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, announced today the presentation of new clinical data for cirtuvivint (SM08502), its…
Read More
Subjects enrolled with biopsy confirmed NASH experienced clinically and statistically significant improvements in liver stiffness as measured by FibroScan, a non-invasive measure of liver fibrosis Subjects with NASH experienced clinically and statistically significant improvements in alanine aminotransferase (ALT), a measure of liver cell inflammation, at both dose levels of AXA1125 Findings demonstrate improvement in hepatic…
Read More
Pharmacokineticic (PK) profile of PrimeC supports the formulation’s extended release properties, as the active components are released simultaneously Excerpt from the Press Release: CAMBRIDGE, Mass., Sept. 28, 2022 /PRNewswire/ — NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) (“NeuroSense”), a company developing treatments for severe neurodegenerative diseases, today announced results from its multi-dose PK study (NCT05436678) of its…
Read More
Initiation of first clinical study of multivalent VBI-2901, designed to increase breadth of protection against COVID-19 and related coronaviruses Preclinical data support broadly reactive immunity of VBI-2901 against a panel of coronavirus variants in mice, which now also includes circulating BA.4 and BA.5 The study is expected to enroll approximately 100 adults in Canada and…
Read More
WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes IND-enabling activities for WVE-006 are underway and Wave expects to submit clinical trial applications for WVE-006 in 2023 Wave is also pioneering new therapeutic…
Read More
Key Points The results of an early-stage clinical trial investigating focused ultrasound to address a possible underlying cause of Parkinson’s disease were published in Movement Disorders. Researchers in Toronto tested the safety and efficacy of focused ultrasound–induced blood-brain barrier opening to deliver enzyme replacement therapy. The procedure was well-tolerated, and a larger study is being…
Read More
CE-VST-01-JC is a novel, allogeneic, off-the-shelf, T cell therapy that targets the JC Virus, the virus that causes progressive multifocal leukoencephalopathy (PML) ASCEND-JC is a randomized, double-blind, placebo-controlled, phase 2 study with sites planned across US, Europe, and Canada Licensed and developed in collaboration with QIMR Berghofer Medical Research Institute’s Professor Rajiv Khanna; NIH’s Irene…
Read More
The SB101 and SB102 studies have together dosed 19 subjects to date This early review of safety sets the stage for further dose escalation Additional safety and cytokine-specific data are expected during the fourth calendar quarter of 2022 Excerpt from the Press Release: PRINCETON, NJ / ACCESSWIRE / September 21, 2022 / Sonnet BioTherapeutics Holdings,…
Read More